Cord Dohrmann - Evotec AG Insider

Evotec AG -- USA Stock  

USD 26.47  0.00  0.00%

Chief Scientific Officer and Member of Management Board

Dr. Cord Dohrmann was Chief Scientific Officer and Member of the Management Board at Evotec AG since September 1, 2010. Dr. Dohrmann has spent over 20 years in biomedical research at academic institutions and in the biotech industry. He started his academic career in 1983 studying Biology at Tuebingen University in Germany and conducting research as a DAAD scholar at Duke University, Durham, USA. Dr. Dohrmann completed his MA thesis at the MaxPlanck Institute in Tuebingen and subsequently enrolled at the Harvard Medical School in Boston, USA, where he received his Ph.D. in Cell and Developmental Biology in 1996. Dr. Dohrmann continued his career as a Shiseido research fellow at the Massachusetts General Hospital in Boston before joining DeveloGen in 1999. He served the company in various management positions including CEO, leading DeveloGen from a startup to an internationally recognized metabolic disease company with a pipeline of innovative preclinical and clinical products for the treatment of diabetes and related disorders
Age: 52  Executive Since 2010      
49 4056 0810  http://www.evotec.com
Dohrmann was advising the European Commission, the MaxPlanckInstitute as well as VC firms and authored and coauthored a number of publications and patents. Since December 2016, Dr. Dohrmann was serving as member of the Supervisory Board of Eternygen GmbH. In June 2017, he became a member of the Supervisory Board of Facio Therapies BV.

Management Efficiency

The company has return on total asset (ROA) of 5.91 % which means that it generated profit of $5.91 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 13.68 % meaning that it generated $13.68 on every $100 dollars invested by stockholders.
The company has accumulated 9.53 M in total debt with debt to equity ratio (D/E) of 2.5 implying the company greatly relies on financing operations through barroing. Evotec AG has Current Ratio of 4.88 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Entity Summary

Evotec AG offer drug discovery solutions to the pharmaceutical, biotechnology, and academic sectors worldwide. Evotec AG (EVOTF) is traded on OTC Market in USA. It is located in Hamburg, and employs 1,000 people.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Evotec AG to your portfolio

Top Management

Evotec AG Leadership Team
Werner Lanthaler, CEO
Claus Braestrup, Executive
Michael Shalmi, Executive, MBA
Mario Polywka, COO, Ph.D
Mary Tanner, Executive
Roland Oetker, Chairman
Andreas Pinkwart, Executive
Paul Herrling, Executive, Ph.D
Colin Bond, CFO, MBA
Cord Dohrmann, Executive
Iris LoewFriedrich, Executive, Ph.D
Bernd Hirsch, Executive
Enno Spillner, CFO
Elaine Sullivan, Executive
Wolfgang Plischke, Chairman, Ph.D

Stock Performance

Evotec AG Performance Indicators